Developer docs
API playgroundTry for free, no card

Search company profiles

Dermavant Sciences

Full company profile

uuid0000fw8

Namestring
Dermavant Sciences
Legal namestring
Dermavant Sciences Ltd.
Websiteurl
dermavant.com
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersLong Beach, United States
HQ citystring
Long Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
topical dermatology therapeutics, plaque psoriasis treatment, atopic dermatitis therapy, biopharmaceutical dermatology, prescription skin treatments
Industry3 codes
1Dermatology Specialty Pharmaceuticals
CodeHLAIACALPrimaryYes
2Psoriasis & Eczema Specialty Care
CodeHLAKACALPrimaryNo
3Dermatology & Aesthetics Pharmaceuticals
CodeHLAIAAAKPrimaryNo
Product category
Dermatology Pharmaceuticals
Social media profiles1 record
Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Dermavant Sciences is a biopharmaceutical company focused on developing and commercializing innovative topical therapeutics for dermatological conditions. Its core product is Tapinarof cream (branded VTAMA), a prescription therapeutic cream indicated for plaque psoriasis and atopic dermatitis. The company operates in the dermatology segment of the pharmaceutical industry, targeting conditions with significant unmet patient need.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Dermavant Sciences is a biopharmaceutical company specializing in immunodermatology. The company's primary product is tapinarof, a therapeutic cream for the treatment of psoriasis and atopic dermatitis. Tapinarof is Dermavant's core pipeline asset that received FDA approval. Dermavant was acquired by Organon & Co. in October 2024 for up to approximately $1.2 billion, and tapinarof (marketed as VTAMA) is now part of Organon's dermatology portfolio alongside their broader general medicines franchise that includes biosimilars and treatments for cardiovascular, neurology, autoimmune, and respiratory conditions.

Product and service1 record
1Tapinarof cream (VTAMA)
CategoryTopical Dermatology Therapeutics
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Arcutis Biotherapeutics
TypeDirect peer
Description

Specialty dermatology biopharma that developed and commercializes ZORYVE (roflumilast cream), a topical therapy approved for both plaque psoriasis and atopic dermatitis — directly overlapping Dermavant's tapinarof indications, patient population, and physician channel.

2Galderma
TypeDirect peer
Description

Pure-play dermatology company with a broad portfolio of branded prescription and aesthetic skin therapeutics, including topical and biologic products for psoriasis, atopic dermatitis, and acne. Comparable to Dermavant as a dermatology-specialized commercial entity.

3LEO Pharma
TypeDirect peer
Description

Global dermatology-focused pharmaceutical company marketing branded topicals and systemics across psoriasis, eczema, and actinic keratosis. Directly comparable to Dermavant as a dermatology-specialty commercial competitor.

4Almirall
TypeDirect peer
Description

European dermatology specialty pharma with a portfolio spanning psoriasis, atopic dermatitis, and actinic keratosis. Directly comparable to Dermavant as a dermatology-focused prescription therapeutics company with overlapping indications.

5AbbVie
TypeBroad incumbent
Description

Large biopharma with leading immunology franchise in psoriasis and atopic dermatitis through Skyrizi (risankizumab) and Rinvoq (upadacitinib). Competes with Dermavant in the same dermatologist-prescribed indications via systemic rather than topical mechanisms.

6Bristol Myers Squibb
TypeBroad incumbent
Description

Marketer of Sotyktu (deucravacitinib), an oral TYK2 inhibitor approved for moderate-to-severe plaque psoriasis. Competes with Dermavant in moderate-to-severe psoriasis via a different mechanism and route of administration.

7Sanofi
TypeBroad incumbent
Description

Co-developer and marketer of Dupixent (dupilumab) with Regeneron, the leading biologic for atopic dermatitis and a competitor in adjacent Type 2 inflammatory skin indications. Comparable as a dermatology/biologic competitor relevant to tapinarof's atopic dermatitis opportunity.

8Amgen
TypeBroad incumbent
Description

Markets Otezla (apremilast), an oral PDE4 inhibitor approved for plaque psoriasis, psoriatic arthritis, and oral ulcers in Behçet's disease. Overlaps with Dermavant in plaque psoriasis via systemic mechanism and dermatologist channel.

9Pfizer
TypeBroad incumbent
Description

Markets Cibinqo (abrocitinib), an oral JAK inhibitor approved for atopic dermatitis, alongside broader inflammation and immunology assets. Competes with Dermavant in moderate-to-severe atopic dermatitis via systemic mechanism.

10AnaptysBio
TypeEmerging player
Description

Clinical-stage immunology biotech developing IL-36R and PD-1 agonist antibodies with potential applications in inflammatory skin disease such as hidradenitis suppurativa and psoriasis. An emerging immunology peer whose inflammatory skin disease pipeline partially overlaps Dermavant's therapeutic focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dermavant Sciences

Dermatology Pharmaceuticalsdermavant.com

Dermavant Sciences firmographics

Firmographics
Name
Dermavant Sciences
Legal name
Dermavant Sciences Ltd.
Website
https://dermavant.com
Company type
Private
Founded year
2016
Operating status
Acquired
Headcount range
251–500 employees
Ownership category
akta.pro rank

Dermavant Sciences industry classification

Industry
Product category
Dermatology Pharmaceuticals
akta.pro primary industry
Dermatology Specialty Pharmaceuticals (HLAIACAL)
akta.pro secondary industries
Psoriasis & Eczema Specialty Care (HLAKACAL), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

Keywords

  • Topical dermatology therapeutics
  • Plaque psoriasis treatment
  • Atopic dermatitis therapy
  • Biopharmaceutical dermatology
  • Prescription skin treatments

Where Dermavant Sciences is headquartered

Location

Headquarters

HQ city
Long Beach
HQ country
United States
HQ region
North America

Markets served

Dermavant Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Dermavant Sciences product offering

Product offering

Core offering

Dermavant Sciences is a biopharmaceutical company focused on developing and commercializing innovative topical therapeutics for dermatological conditions. Its core product is Tapinarof cream (branded VTAMA), a prescription therapeutic cream indicated for plaque psoriasis and atopic dermatitis. The company operates in the dermatology segment of the pharmaceutical industry, targeting conditions with significant unmet patient need.

Product overview

Dermavant Sciences is a biopharmaceutical company specializing in immunodermatology. The company's primary product is tapinarof, a therapeutic cream for the treatment of psoriasis and atopic dermatitis. Tapinarof is Dermavant's core pipeline asset that received FDA approval. Dermavant was acquired by Organon & Co. in October 2024 for up to approximately $1.2 billion, and tapinarof (marketed as VTAMA) is now part of Organon's dermatology portfolio alongside their broader general medicines franchise that includes biosimilars and treatments for cardiovascular, neurology, autoimmune, and respiratory conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Tapinarof cream (VTAMA)

Companies that use Dermavant Sciences

Customer profile

Segments1 record

Ideal customer profiles2 records

Dermavant Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Dermavant Sciences partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Dermavant Sciences competitors and assessment

Company assessment

Direct peers

  • Arcutis Biotherapeutics: Specialty dermatology biopharma that developed and commercializes ZORYVE (roflumilast cream), a topical therapy approved for both plaque psoriasis and atopic dermatitis — directly overlapping Dermavant's tapinarof indications, patient population, and physician channel.
  • Galderma: Pure-play dermatology company with a broad portfolio of branded prescription and aesthetic skin therapeutics, including topical and biologic products for psoriasis, atopic dermatitis, and acne. Comparable to Dermavant as a dermatology-specialized commercial entity.
  • LEO Pharma: Global dermatology-focused pharmaceutical company marketing branded topicals and systemics across psoriasis, eczema, and actinic keratosis. Directly comparable to Dermavant as a dermatology-specialty commercial competitor.
  • Almirall: European dermatology specialty pharma with a portfolio spanning psoriasis, atopic dermatitis, and actinic keratosis. Directly comparable to Dermavant as a dermatology-focused prescription therapeutics company with overlapping indications.

Broad incumbents

  • AbbVie: Large biopharma with leading immunology franchise in psoriasis and atopic dermatitis through Skyrizi (risankizumab) and Rinvoq (upadacitinib). Competes with Dermavant in the same dermatologist-prescribed indications via systemic rather than topical mechanisms.
  • Bristol Myers Squibb: Marketer of Sotyktu (deucravacitinib), an oral TYK2 inhibitor approved for moderate-to-severe plaque psoriasis. Competes with Dermavant in moderate-to-severe psoriasis via a different mechanism and route of administration.
  • Sanofi: Co-developer and marketer of Dupixent (dupilumab) with Regeneron, the leading biologic for atopic dermatitis and a competitor in adjacent Type 2 inflammatory skin indications. Comparable as a dermatology/biologic competitor relevant to tapinarof's atopic dermatitis opportunity.
  • Amgen: Markets Otezla (apremilast), an oral PDE4 inhibitor approved for plaque psoriasis, psoriatic arthritis, and oral ulcers in Behçet's disease. Overlaps with Dermavant in plaque psoriasis via systemic mechanism and dermatologist channel.
  • Pfizer: Markets Cibinqo (abrocitinib), an oral JAK inhibitor approved for atopic dermatitis, alongside broader inflammation and immunology assets. Competes with Dermavant in moderate-to-severe atopic dermatitis via systemic mechanism.

Emerging players

  • AnaptysBio: Clinical-stage immunology biotech developing IL-36R and PD-1 agonist antibodies with potential applications in inflammatory skin disease such as hidradenitis suppurativa and psoriasis. An emerging immunology peer whose inflammatory skin disease pipeline partially overlaps Dermavant's therapeutic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Dermavant Sciences social profiles

Digital presence

Dermavant Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dermavant Sciences leadership team

Management profile

Number of profiles

Profiles3 records

Dermavant Sciences funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dermavant Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dermavant Sciences

What does Dermavant Sciences do?

Dermavant Sciences is a biopharmaceutical company focused on developing and commercializing innovative topical therapeutics for dermatological conditions. Its core product is Tapinarof cream (branded VTAMA), a prescription therapeutic cream indicated for plaque psoriasis and atopic dermatitis. The company operates in the dermatology segment of the pharmaceutical industry, targeting conditions with significant unmet patient need.

Is Dermavant Sciences a public or private company?

Dermavant Sciences is a private company. It is classified as corporate owned and is currently acquired.

When was Dermavant Sciences founded?

Dermavant Sciences was founded in 2016. It employs 251 to 500 people.

Where is Dermavant Sciences based?

Dermavant Sciences is headquartered in Long Beach, United States, in the North America region.

Who are Dermavant Sciences's main competitors?

Direct peers on record are Arcutis Biotherapeutics, Galderma, LEO Pharma and Almirall. Broad incumbents are AbbVie, Bristol Myers Squibb, Sanofi, Amgen and Pfizer. AnaptysBio is listed as an emerging player.

Does Dermavant Sciences have an API?

No public API is recorded for Dermavant Sciences.

What industry is Dermavant Sciences in?

Dermavant Sciences's product category is Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of HLAKACAL, Psoriasis & Eczema Specialty Care.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comEmerging Sub-Segments Transforming the Palmoplantar Pustulosis Market LandscapeThe palmoplantar pustulosis market is projected to reach $3.03 billion by 2030, growing at a compound annual growth rate of 7.6%, driven by new biologic drugs, targeted immunomodulators, and expanded teledermatology platforms. In October 2024, Organon & Co. acquired Dermavant Sciences Ltd. to expand its dermatology portfolio and women's health offerings, while in December 2024, CN Water Systems Pvt. Ltd. launched an energy-efficient water for injection system targeting pharmaceutical manufacturing cost savings.PR NewswireAHR Agonists Market Trends Signal Promising Growth in Immunology and Dermatology Therapeutics | DelveInsightDelveInsight released a market research report projecting significant growth in the AHR agonists market across leading markets (US, EU4, UK, Japan) by 2034, driven by the FDA approval of VTAMA (tapinarof) and rising autoimmune disease prevalence. In October 2024, Organon completed its acquisition of Dermavant Sciences, gaining full rights to VTAMA for plaque psoriasis and atopic dermatitis. Several companies including Azora Therapeutics and Aqilion are actively developing investigational AHR agonists for inflammatory and autoimmune conditions.RoivantCompany OverviewRoivant Sciences describes its business model of developing medicines through agile subsidiaries known as Vants, noting that these entities have conducted 12 positive Phase 3 trials since 2019. The company highlights the 2022 launch of VTAMA for plaque psoriasis and mentions that Organon acquired Dermavant in 2024.SimcodermEczema Clinical Study News Review Quarter 1 2024This article reviews clinical research developments in eczema treatment during the first quarter of 2024, highlighting multiple drug candidates showing efficacy and several regulatory milestones. Key events include FDA approvals for Tralokinumab and Roflumilast foam, positive Phase II/III results from companies such as Dermavant and Galderma, and a clinical hold placed on RAPT Therapeutics' trials due to safety concerns.Roots AnalysisAtopic Dermatitis Market Size, Share, Trends, & Insights Report, 2035A market research report projects the global atopic dermatitis market to grow from USD 13.69 billion in 2025 to USD 31.86 billion by 2035, driven by rising prevalence of the condition and advancements in biologics and digital therapeutics. The analysis highlights key players such as Sanofi, Pfizer, and AbbVie dominating the landscape with targeted therapies, while noting challenges like high treatment costs and side effects. Regulatory approvals, including FDA acceptance for Dermavant Science's VTAMA cream, underscore ongoing innovation in treatment modalities.BenzingaMarching Towards FDA Approval: Dermavant's Vtama Cream Excels in Phase 3 Trial, Eyes 2024 Submission - RoDermavant Sciences, a subsidiary of Roivant Sciences, announced positive results from the ADORING 1 Phase 3 trial of Vtama (tapinarof) cream for atopic dermatitis, with 45.4% of subjects achieving clear or almost clear skin at Week 8 and statistically significant improvements in itch symptoms. The company plans to submit a supplemental marketing application to the FDA in Q1 2024, following positive topline data from the ADORING 2 trial announced in March. Vtama previously received FDA approval for psoriasis in 2022.BenzingaThe Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment IThis article summarizes multiple recent developments in the biotech sector, including FDA clinical holds on INmune Bio's Alzheimer's trial and Caladrius Biosciences halting enrollment in its heart disease study. It also highlights positive regulatory milestones, such as the FDA approvals of United Therapeutics' Tyvaso DPI and Dermavant Sciences' Vtama cream, alongside Merck & Co's Keytruda approval in Europe.NovaquestDermavant Announces $200 Million of FinancingDermavant Sciences has announced a $160 million revenue interest sale agreement for its investigational product tapinarof, with participation from Marathon Asset Management and NovaQuest Capital Management, contingent on FDA approval. Additionally, Dermavant has secured a $40 million loan under a senior secured credit facility with a Boston-based firm. The funds will be used to cover milestone payments tied to the approval and launch of tapinarof for treating psoriasis and to enhance commercial preparations.GlobeNewswireRoivant Sciences Reports Financial Results for the Quarter Ended September 30, 2021 and Provides Business UpdateRoivant Sciences reported Q2 2021 results with a net loss of $225.6 million and cash balance of $2.5 billion. Dermavant's tapinarof study showed 58.2% of patients achieved a PGA score of 0 or 1, and Aruvant reported zero vaso-occlusive events in sickle cell patients. The company expects FDA approval for tapinarof in Q2 2022.FinSMEsDermavant Sciences Raises $200M in FundingDermavant Sciences raised $200 million through a $160 million revenue interest purchase agreement with Marathon Asset Management, NovaQuest Capital Management, and another institutional investor, alongside a $40 million senior secured credit facility. The company intends to use the proceeds to pay milestone obligations related to the potential US approval of its investigational psoriasis treatment tapinarof and for general corporate purposes.